Salmon S A, Watts J L, Case C A, Hoffman L J, Wegener H C, Yancey R J
Upjohn Company, Kalamazoo, Michigan 49001, USA.
J Clin Microbiol. 1995 Sep;33(9):2435-44. doi: 10.1128/jcm.33.9.2435-2444.1995.
The MICs of ceftiofur and other antimicrobial agents, tested for comparison, for 515 bacterial isolates of pigs from the United States, Canada, and Denmark with various diseases were compared. The organisms tested included Actinobacillus pleuropneumoniae, Escherichia coli, Pasteurella multocida, Salmonella choleraesuis, Salmonella typhimurium, Streptococcus suis, Streptococcus dysgalactiae subsp. equisimilis, Streptococcus equi subsp. equi, and Streptococcus equi subsp. zooepidemicus. In addition to ceftiofur, the following antimicrobial agents or combinations were tested: enrofloxacin, ampicillin, sulfamethazine, trimethoprim-sulfadiazine (1:19), erythromycin, lincomycin, spectinomycin, lincomycin-spectinomycin (1:8), tilmicosin, and tetracycline. Tilmicosin was only tested against the U.S. isolates. Overall, ceftiofur and enrofloxacin were the most active antimicrobial agents tested against all isolates, with MICs inhibiting 90% of isolates tested (MIC90s) of < or = 2.0 and < or = 1.0 microgram/ml, respectively. Erythromycin, sulfamethazine, spectinomycin, and lincomycin demonstrated limited activity against all of the organisms tested, with MIC90s of > or = 8.0, > or = 256.0, > or = 32.0, and > or = 16.0 micrograms/ml, respectively. Trimethoprim-sulfadiazine was active against isolates of A. pleuropneumoniae, S. choleraesuis, S. typhimurium, P. multocida, S. equi, and S. suis (MIC90s, < or = 0.5 microgram/ml) but was less active against the E. coli strains tested (MIC90, > 16.0 micrograms/ml). Ampicillin was active against the P. multocida, S. suis, and S. equi isolates tested (MIC90s, 0.5, 0.06, and 0.06 micrograms/ml, respectively) and was moderately active against S. typhimurium (MIC90s, 2.0 micrograms/ml). However, this antimicrobial agent was much less active when it was tested against A. pleuropneumoniae, S. cholerae-suis, and E. coli (MIC90s, 16.0, > 32.0, and 32.0 micrograms/ml, respectively). Against the U.S. isolates of A. pleuropneumoniae and P. multocida, tilmicosin was moderately active (MIC90s, 4.0 and 8.0 micrograms/ml, respectively). However, this compound was not active against the remaining U.S. isolates (MIC90s, > 64.0 micrograms/ml). Differences in the MICs from one country to another were not detected with enrofloxacin, ceftiofur, or lincomycin for the strains tested, but variations in the MICs of the remaining antimicrobial agents were observed.
对来自美国、加拿大和丹麦的患有各种疾病的515株猪源细菌分离株,比较了头孢噻呋和其他用于对照测试的抗菌剂的最低抑菌浓度(MIC)。所测试的微生物包括胸膜肺炎放线杆菌、大肠杆菌、多杀性巴氏杆菌、猪霍乱沙门氏菌、鼠伤寒沙门氏菌、猪链球菌、马链球菌兽疫亚种、马链球菌马亚种和马链球菌类马亚种。除头孢噻呋外,还测试了以下抗菌剂或组合:恩诺沙星、氨苄西林、磺胺二甲嘧啶、甲氧苄啶 - 磺胺嘧啶(1:19)、红霉素、林可霉素、壮观霉素、林可霉素 - 壮观霉素(1:8)、替米考星和四环素。替米考星仅针对美国分离株进行了测试。总体而言,头孢噻呋和恩诺沙星是针对所有分离株测试中活性最高的抗菌剂,其抑制90%测试分离株的MIC(MIC90)分别≤2.0微克/毫升和≤1.0微克/毫升。红霉素、磺胺二甲嘧啶、壮观霉素和林可霉素对所有测试微生物的活性有限,其MIC90分别≥8.0微克/毫升、≥256.0微克/毫升、≥32.0微克/毫升和≥16.0微克/毫升。甲氧苄啶 - 磺胺嘧啶对胸膜肺炎放线杆菌、猪霍乱沙门氏菌、鼠伤寒沙门氏菌、多杀性巴氏杆菌、马链球菌和猪链球菌的分离株有活性(MIC90≤0.5微克/毫升),但对所测试的大肠杆菌菌株活性较低(MIC90>16.0微克/毫升)。氨苄西林对所测试的多杀性巴氏杆菌、猪链球菌和马链球菌分离株有活性(MIC90分别为0.5、0.06和0.06微克/毫升),对鼠伤寒沙门氏菌有中等活性(MIC90为2.0微克/毫升)。然而,当针对胸膜肺炎放线杆菌、猪霍乱沙门氏菌和大肠杆菌进行测试时,这种抗菌剂的活性要低得多(MIC90分别为16.0、>32.0和32.0微克/毫升)。针对美国胸膜肺炎放线杆菌和多杀性巴氏杆菌分离株,替米考星有中等活性(MIC90分别为4.0和8.0微克/毫升)。然而,该化合物对其余美国分离株无活性(MIC90>64.0微克/毫升)。在所测试的菌株中,未检测到恩诺沙星、头孢噻呋或林可霉素在不同国家之间的MIC差异,但观察到其余抗菌剂的MIC存在变化。